Filtering by:
ImmunotherapyResearchers Report Advances in Lung Cancer Immunotherapy
Scientists presenting at the American Association for Cancer Research Annual Meeting in Chicago have found new and promising ways to use immunotherapy to treat people with some types of non-small cell lung cancer (NSCLC).
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
Year in Review: Cancer Research Insights from 2017
Read highlights about American Cancer Society research from 2017.
FDA Approves Yescarta (Axicabtagene Ciloleucel) for Adults with Certain Lymphomas
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel) to treat adults with certain types of large B-Cell lymphoma.
Could Infections Teach Us How to Make Treatments for Pediatric ALL Even Better?
Alix Seif, MD, MPH, is studying a new type of immunotherapy that could teach the immune system long-term memory. The goal is for the immune system to kill any new leukemia cells for the rest of the child's life.
FDA Approves Keytruda (Pembrolizumab) for Stomach Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) to treat people with certain cancers of the stomach or gastroesophageal junction, the area where the stomach connects to the esophagus.
FDA Approves Opdivo (Nivolumab) for Liver Cancer
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab), a monoclonal antibody, which is a type of immunotherapy, to treat liver cancer.